VERTEX PHARMACEUTICALS INC/ US92532F1003 /
| 11/15/2024 5:32:14 PM | Chg. -26.90 | Volume | Bid5:32:14 PM | Ask5:32:14 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 437.35EUR | -5.79% | 25 Turnover: 11,368.15 |
-Bid Size: - | -Ask Size: - | 113.92 bill.EUR | - | - |
Assets
| 2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 696.9000 | 715.8120 | 697.7150 | 698.3620 | 789.4370 | ||||||
| Intangible Assets | 0.0000 | 29 | 284.3400 | 284.3400 | 29 | ||||||
| Long-Term Investments | .1000 | - | - | 20.2760 | 20.4470 | ||||||
| Fixed Assets | - | 788.1680 | 1,091.7220 | - | 897.0510 | ||||||
| Inventories | 14.1000 | 30.8480 | 57.2070 | 77.6040 | 111.8300 | ||||||
| Accounts Receivable | 85.5000 | 75.9640 | 177.6390 | 201.0830 | 281.3430 | ||||||
| Cash and Cash Equivalents | 569.3000 | 625.2590 | 714.7680 | 1,183.9450 | 1,665.4120 | ||||||
| Current Assets | 1,588.6000 | 1,546.5110 | 1,407.1530 | 1,831.5400 | 2,648.9630 | ||||||
| Total Assets | 2,319 | 2,334.6790 | 2,498.8750 | 2,896.7870 | 3,546.0140 | ||||||
Liabilities
| 2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 49.3000 | 71.1940 | 74.9420 | 61.4510 | 73.9940 | ||||||
| Long-term debt | - | 792.9350 | 739.3970 | 521.3350 | 583.9020 | ||||||
| Liabilities to Banks | 0.0000 | 280.6000 | 224 | 0.0000 | 0.0000 | ||||||
| Provisions | - | - | 110.4000 | 134.1000 | 6.3000 | ||||||
| Liabilities | 962.6000 | 1,238.4960 | 1,405.2470 | 1,558.5960 | 1,503.7080 | ||||||
| Share Capital | - | 2.3850 | 2.4270 | 2.4500 | 2.5120 | ||||||
| Total Equity | 1,356.4000 | 1,096.1830 | 1,093.6280 | 1,338.1910 | 2,042.3060 | ||||||
| Minority Interests | 0.0000 | 21.1770 | 153.6610 | 181.6090 | 13.7270 | ||||||
| Total liabilities equity | 2,319 | 2,334.6790 | 2,498.8750 | 2,896.7870 | 3,546.0140 | ||||||
Income Statement
| 2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 1,212 | 580.4150 | 1,032.3360 | 1,702.1770 | 2,488.6520 | ||||||
| Depreciation (total) | - | 63.2570 | 62.3430 | 61.3980 | 61.3970 | ||||||
| Operating Result | -903.4000 | -692.4120 | -466.8790 | 9.9360 | 123.2430 | ||||||
| Interest Income | -22.7000 | 72.8630 | 84.2060 | 81.4320 | 57.5500 | ||||||
| Income Before Taxes | -976.1000 | -734.8750 | -557.8000 | -67.3660 | -15.6890 | ||||||
| Income Taxes | -288.6000 | 6.9580 | 30.3810 | 16.6650 | -107.3240 | ||||||
| Minority Interests Profit | 242.5000 | 4.1900 | 31.8470 | -28.0210 | 171.8490 | ||||||
| Net Income | -445 | -738.5550 | -556.3340 | -112.0520 | 263.4840 | ||||||
Per Share
Cash Flow
| 2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | -51.6000 | -513.1990 | -365.4320 | 236.1030 | 844.9420 | ||||||
| Cash Flow from Investing Activities | -54.1000 | 73.9590 | 268.8560 | 104.4690 | -437.6810 | ||||||
| Cash Flow from Financing | 180.9000 | 497.3760 | 188.9190 | 133.2710 | 68.4040 | ||||||
| Decrease / Increase in Cash | 79.9000 | 55.9600 | 89.5090 | 469.1770 | 481.4670 | ||||||
| Employees | 1,800 | 1,830 | 1,950 | 2,150 | 2,300 | ||||||
